JP6215230B2 - イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド - Google Patents
イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド Download PDFInfo
- Publication number
- JP6215230B2 JP6215230B2 JP2014552376A JP2014552376A JP6215230B2 JP 6215230 B2 JP6215230 B2 JP 6215230B2 JP 2014552376 A JP2014552376 A JP 2014552376A JP 2014552376 A JP2014552376 A JP 2014552376A JP 6215230 B2 JP6215230 B2 JP 6215230B2
- Authority
- JP
- Japan
- Prior art keywords
- pain
- alkyl
- heterocycloalkyl
- pharmaceutically acceptable
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*CNCCO Chemical compound C*CNCCO 0.000 description 13
- GOBOPEILQWUUIZ-UHFFFAOYSA-N CC(C)(c(c(OC)c1)ccc1C(O)=O)OC Chemical compound CC(C)(c(c(OC)c1)ccc1C(O)=O)OC GOBOPEILQWUUIZ-UHFFFAOYSA-N 0.000 description 1
- NCHALTLJMYEGKC-UHFFFAOYSA-N CC(C)OC(C1)CC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)OC1c1cccnc1 Chemical compound CC(C)OC(C1)CC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)OC1c1cccnc1 NCHALTLJMYEGKC-UHFFFAOYSA-N 0.000 description 1
- CHBAGYMIALAXSM-UHFFFAOYSA-N CC(C)OC1C=C(c2cccnc2)OC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)C1 Chemical compound CC(C)OC1C=C(c2cccnc2)OC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)C1 CHBAGYMIALAXSM-UHFFFAOYSA-N 0.000 description 1
- JPSTUQPACLGNOB-UHFFFAOYSA-N CC(C)Oc(c(C)c1)ccc1C(N(CC1)CC2C1(CC(CC(c1cnccc1)=O)=O)OC2)=O Chemical compound CC(C)Oc(c(C)c1)ccc1C(N(CC1)CC2C1(CC(CC(c1cnccc1)=O)=O)OC2)=O JPSTUQPACLGNOB-UHFFFAOYSA-N 0.000 description 1
- ZPEVMSYTWNXDJX-UHFFFAOYSA-N CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1(C1)OC(c2cccnc2)=CC1=O)=O Chemical compound CC(C)Oc(c(C)c1)ccc1C(N(CC1)CCC1(C1)OC(c2cccnc2)=CC1=O)=O ZPEVMSYTWNXDJX-UHFFFAOYSA-N 0.000 description 1
- AJSFIQYMDNCBQU-UHFFFAOYSA-N CC(C)Oc(cc1)c(C)cc1C(N)=O Chemical compound CC(C)Oc(cc1)c(C)cc1C(N)=O AJSFIQYMDNCBQU-UHFFFAOYSA-N 0.000 description 1
- LPXNGYUJZLWMPO-UHFFFAOYSA-N CC(C)Oc(cc1)c(C)cc1C(O)=O Chemical compound CC(C)Oc(cc1)c(C)cc1C(O)=O LPXNGYUJZLWMPO-UHFFFAOYSA-N 0.000 description 1
- JIDRJYBQEIPGRF-UHFFFAOYSA-N CC(C)Oc(ccc(C(O)=O)c1)c1OC Chemical compound CC(C)Oc(ccc(C(O)=O)c1)c1OC JIDRJYBQEIPGRF-UHFFFAOYSA-N 0.000 description 1
- LRHXHRCWOHXOTL-UHFFFAOYSA-N CCOC(C1)CC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)OC1c1ccncc1 Chemical compound CCOC(C1)CC(CC2)(CCN2C(c(cc2C)ccc2OC(C)C)=O)OC1c1ccncc1 LRHXHRCWOHXOTL-UHFFFAOYSA-N 0.000 description 1
- UEVXVBKBOFGKIN-UHFFFAOYSA-N COc1cc(C(O)=O)ccc1Br Chemical compound COc1cc(C(O)=O)ccc1Br UEVXVBKBOFGKIN-UHFFFAOYSA-N 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N Cc1ccccc1N Chemical compound Cc1ccccc1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- LEEKWJRUIWHKIL-UHFFFAOYSA-N O=S(C(F)F)(S)=O Chemical compound O=S(C(F)F)(S)=O LEEKWJRUIWHKIL-UHFFFAOYSA-N 0.000 description 1
- KTDYNXHVUZGFLI-UHFFFAOYSA-N O=S(NC1CC1)(S)=O Chemical compound O=S(NC1CC1)(S)=O KTDYNXHVUZGFLI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586875P | 2012-01-16 | 2012-01-16 | |
| US61/586,875 | 2012-01-16 | ||
| PCT/US2013/021535 WO2013109521A1 (en) | 2012-01-16 | 2013-01-15 | Pyran-spirocyclic piperidine amides as modulators of ion channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505321A JP2015505321A (ja) | 2015-02-19 |
| JP2015505321A5 JP2015505321A5 (https=) | 2016-03-03 |
| JP6215230B2 true JP6215230B2 (ja) | 2017-10-18 |
Family
ID=47595110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552376A Active JP6215230B2 (ja) | 2012-01-16 | 2013-01-15 | イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9403839B2 (https=) |
| EP (1) | EP2804868B1 (https=) |
| JP (1) | JP6215230B2 (https=) |
| CN (1) | CN104136442B (https=) |
| AU (1) | AU2013209958B2 (https=) |
| CA (1) | CA2863343A1 (https=) |
| ES (1) | ES2631611T3 (https=) |
| MX (1) | MX2014008591A (https=) |
| NZ (1) | NZ627259A (https=) |
| WO (1) | WO2013109521A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| KR102731924B1 (ko) * | 2017-11-01 | 2024-11-19 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
| CN108276307A (zh) * | 2018-01-17 | 2018-07-13 | 常熟浸大科技有限公司 | 3-氰基-4-烃氧基苯甲酸酯的合成方法 |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US121652A (en) | 1871-12-05 | Improvement in picture-frame hangers | ||
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE69633245T2 (de) * | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
| US20060052597A1 (en) * | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| US7576207B2 (en) * | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| EP2231655B1 (en) * | 2007-11-13 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| CN101910166A (zh) * | 2007-11-13 | 2010-12-08 | 沃泰克斯药物股份有限公司 | 用作钠离子通道调节剂的杂环衍生物 |
| RU2011103451A (ru) * | 2008-07-01 | 2012-08-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| WO2010151815A2 (en) * | 2009-06-25 | 2010-12-29 | Abbott Laboratories | 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof |
| WO2010151597A1 (en) * | 2009-06-26 | 2010-12-29 | Schering Corporation | Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers |
| JP5940562B2 (ja) * | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| MX347982B (es) * | 2011-03-14 | 2017-05-22 | Vertex Pharma | Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos. |
-
2013
- 2013-01-15 JP JP2014552376A patent/JP6215230B2/ja active Active
- 2013-01-15 ES ES13700841T patent/ES2631611T3/es active Active
- 2013-01-15 AU AU2013209958A patent/AU2013209958B2/en not_active Expired - Fee Related
- 2013-01-15 MX MX2014008591A patent/MX2014008591A/es unknown
- 2013-01-15 EP EP13700841.3A patent/EP2804868B1/en active Active
- 2013-01-15 CN CN201380010104.4A patent/CN104136442B/zh not_active Expired - Fee Related
- 2013-01-15 NZ NZ627259A patent/NZ627259A/en not_active IP Right Cessation
- 2013-01-15 WO PCT/US2013/021535 patent/WO2013109521A1/en not_active Ceased
- 2013-01-15 CA CA2863343A patent/CA2863343A1/en not_active Abandoned
- 2013-01-15 US US14/372,353 patent/US9403839B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104136442B (zh) | 2016-12-21 |
| JP2015505321A (ja) | 2015-02-19 |
| US20150005304A1 (en) | 2015-01-01 |
| CN104136442A (zh) | 2014-11-05 |
| EP2804868A1 (en) | 2014-11-26 |
| EP2804868B1 (en) | 2017-04-12 |
| AU2013209958B2 (en) | 2017-09-07 |
| CA2863343A1 (en) | 2013-07-25 |
| WO2013109521A1 (en) | 2013-07-25 |
| AU2013209958A1 (en) | 2014-08-07 |
| US9403839B2 (en) | 2016-08-02 |
| MX2014008591A (es) | 2014-08-22 |
| NZ627259A (en) | 2016-12-23 |
| ES2631611T3 (es) | 2017-09-01 |
| HK1203074A1 (zh) | 2015-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6215230B2 (ja) | イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド | |
| JP5940562B2 (ja) | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド | |
| JP6261558B2 (ja) | イオンチャネルのモジュレーターとしてのピロロピラジン−スピロ環式ピペリジンアミド | |
| JP6605462B2 (ja) | イオンチャネルのモジュレーターとしての縮合ピペリジンアミド | |
| EP2686325B1 (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels | |
| WO2014022639A1 (en) | Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone | |
| HK1203074B (en) | Pyran-spirocyclic piperidine amides as modulators of ion channels | |
| HK1223611B (en) | Fused piperidine amides as modulators of ion channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160113 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160914 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170825 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170920 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6215230 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |